Fig. 4.

Comparing the efficacy results in MiniPDX assays and results in PDX assays. a Representative results of pairwise efficacy tests in 4 PDX xenograft models against S-1 regimens in the same row (See Table 3 for detailed information). Note: Similar results were observed in MiniPDX assays (lower panel, tumor cell viability) as those in PDX assay (upper panel, tumor growth curve). After the treatment, GAYW5 and GAYW7 showed a marked decrease in tumor volume or cell viability but GAYL1 and GAYB7 did not. b Pairwise efficacy test in Model CTC15063 against erlotinib and AZD9291 in the same row. The efficacy results of MiniPDX (lower panel, tumor cell viability) are consistent with those in PDX models (upper panel, tumor growth curve). (n = 6, values showing are mean ± SEM; *P < 0.05; **P < 0.01 in comparison to the vehicle group, paired Student’s t test)